# Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication

> **NCT05469685** · PHASE4 · COMPLETED · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 914 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Amoxicillin

## Key facts

- **NCT ID:** NCT05469685
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-01
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-09-30
- **Target enrollment:** 914 (ACTUAL)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05469685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05469685, "Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05469685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*